Only two antidepressants carry FDA approval for treating major depressive disorder in teenagers: fluoxetine (Prozac), approved for ages 8 and up, and escitalopram (Lexapro), approved for ages 12 and up. Both are selective serotonin reuptake inhibitors, or SSRIs, and both have demonstrated clear benefits over placebo in clinical trials. That said, choosing the right medication involves more than picking one off a list. How well it works, what side effects to expect, and whether therapy should come first or alongside it all matter.
The Two FDA-Approved Options
Fluoxetine is the most studied antidepressant in young people and the only one approved for children as young as 8. It works by blocking the recycling of serotonin, a chemical messenger involved in mood regulation, so more of it stays active in the brain for longer. For depression in teenagers, treatment typically starts at a low daily dose and may be increased after a week or more if needed. Fluoxetine also has a notably long half-life, meaning it lingers in the body longer than other SSRIs. This can be an advantage: if a teen misses a dose, they’re less likely to experience withdrawal-like symptoms.
Escitalopram is the other approved option, available for adolescents 12 and older. Its approval was based on an eight-week trial comparing it to placebo in outpatients aged 12 to 17. Teens taking escitalopram showed significantly greater improvement on a standardized depression rating scale. It tends to be well tolerated and is sometimes preferred when a prescriber wants a medication with fewer drug interactions than fluoxetine.
Beyond these two, doctors sometimes prescribe other SSRIs like sertraline off-label for teen depression. In one large European study, sertraline was the second most commonly prescribed antidepressant for young people, and about two-thirds of those prescriptions were off-label (meaning for a condition or age group not specifically approved on the drug’s label). Off-label prescribing is legal and common in pediatric medicine, but it means the evidence base is thinner.
Medication Works Better With Therapy
The largest study ever conducted on teen depression treatment, known as the TADS study, compared fluoxetine alone, cognitive behavioral therapy (CBT) alone, and the two combined. At 12 weeks, 73% of teens receiving both medication and therapy responded to treatment, compared to 62% on fluoxetine alone and 48% with therapy alone. By 36 weeks, the combination group still held a slight edge at 86%, though fluoxetine alone and therapy alone had both climbed to 81%.
The takeaway is practical: medication alone can work, and therapy alone can work, but combining them gives the best shot at improvement, especially in the early months when symptoms are most disruptive to school, friendships, and daily life. CBT teaches teens concrete skills for managing negative thought patterns, and those skills persist even after treatment ends.
Common Side Effects in Teens
SSRIs produce a somewhat distinct side effect profile in adolescents compared to adults. The most commonly reported issues include stomach pain, nausea, trouble sleeping, drowsiness, and a cluster of symptoms sometimes called “activation,” which can look like restlessness, irritability, increased anxiety, or feeling wired. Activation can be unsettling for both teens and parents, but it’s recognized as a known early side effect rather than a sign the medication is making things worse overall.
The encouraging news is that many of these side effects are transient. In one clinical trial tracking physical symptoms over 12 weeks, the severity of insomnia, restlessness, nausea, and stomach pain all decreased significantly from baseline as treatment continued. Starting at a lower dose and increasing gradually helps minimize these early effects.
Sexual side effects are well documented in adults taking SSRIs, including reduced desire and difficulty with orgasm. Very little research has examined these effects in adolescents specifically, which is a notable gap given that teens may not volunteer this information to a parent or prescriber. It’s worth knowing this is a possibility so your teen feels comfortable raising it.
The Black Box Warning on Suicidal Thinking
All antidepressants carry an FDA black box warning about an increased risk of suicidal thoughts and behavior in people under 25. The data behind this warning comes from a pooled analysis of clinical trials: among young people taking antidepressants, 4% experienced suicidal thoughts, compared to 2% on placebo. No completed suicides occurred in any of the trials analyzed.
This warning does not mean antidepressants cause suicide. It means that in the first few months of treatment, a small percentage of young people experience a temporary increase in suicidal thinking. This is precisely why close monitoring matters so much early on, and why untreated depression, which itself carries a serious suicide risk, has to be weighed against this relatively small treatment-related risk.
What Monitoring Looks Like Early On
Clinical guidelines recommend at least weekly contact during the first four weeks of antidepressant treatment for a teenager. These check-ins don’t always need to be with the prescribing doctor; they can involve a therapist, school counselor, or structured parent observations. The goal is to watch for changes in mood, any new or worsening suicidal thoughts, increased irritability or hostility, and side effects that might make a teen want to quit the medication.
Some prescribers limit early prescriptions to a one-week supply at a time during this initial period. A formal review with the prescriber typically happens at the four-to-six-week mark to assess whether the medication is helping, whether the dose needs adjusting, or whether a switch makes sense. Full therapeutic effects often take four to six weeks to appear, so patience during this window is important. If a teen feels no different after two weeks, that alone isn’t a reason to stop.
How the Right Medication Gets Chosen
In practice, most prescribers start with fluoxetine because it has the strongest evidence base in young people. Escitalopram is a common second choice, particularly for teens 12 and older. If one SSRI doesn’t work or produces intolerable side effects, switching to another is standard. Factors like family history of response to a particular medication, the teen’s other symptoms (anxiety often accompanies depression), and potential interactions with other medications all play into the decision.
There is no blood test or brain scan that predicts which antidepressant will work best for a given teenager. The process sometimes involves trial and adjustment, which can feel frustrating. What the evidence consistently shows is that SSRIs as a class are effective for adolescent depression, that combining them with therapy produces the best outcomes, and that close monitoring during the first month or two makes treatment safer.